CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
bevacizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00290810
NCT00290810Phase 2Completed
CompareCT.gov

A Phase II Trial of Bevacizumab to Prevent or Delay Disease Progression in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

National Cancer Institute (NCI)·interventional·Posted Feb 13, 2006·Updated May 9, 2014

In Brief

A Phase 2 clinical trial evaluating bevacizumab for B-cell Chronic Lymphocytic Leukemia and Refractory Chronic Lymphocytic Leukemia. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This phase II trial is studying how well bevacizumab works in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2006
Enrollment StartDec 1, 2005
Primary CompletionOct 1, 2008
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.4 years ago

Interventions

bevacizumabbiological

Given IV